Ceftibuten dihydrate suspension

• Post Date:

  Jul 04,2015

• Expiry Date:

  Dec 31,2015

• Detailed Description:

  ceftibuten dihydrate suspension,CEDAX,produced by Schering plough
  
  CEDAX (ceftibuten) is indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see DOSAGE AND ADMINISTRATION and Clinical Studies sections).
  Acute Bacterial Exacerbations of Chronic Bronchitis due toHaemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pneumoniae (penicillin-susceptible strains only).
  NOTE: In acute bacterial exacerbations of chronic bronchitis clinical trials where Moraxella catarrhalis was isolated from infected sputum at baseline, ceftibuten clinical efficacy was 22% less than control.
  Acute Bacterial Otitis Media due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pyogenes.
  NOTE: Although ceftibuten used empirically was equivalent to comparators in the treatment of clinically and/or microbiologically documented acute otitis media, the efficacy against Streptococcus pneumoniae was 23% less than control. Therefore, ceftibuten should be given empirically only when adequate antimicrobial coverage against Streptococcus pneumoniae has been previously administered.
  Pharyngitis and Tonsillitis due to Streptococcus pyogenes.
  NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Ceftibuten is generally effective in the eradication of Streptococcus pyogenes from theoropharynx; however, data establishing the efficacy of the CEDAX (ceftibuten) product for the prophylaxis of subsequent rheumatic fever are not available.

• Company:

  Linyi Lab Pharmaceutical Technology Co., Ltd     [ China ]        

• Contact:

  luo zhaoliang

• Tel:

  +86-15092968958

• Fax:

• Email:

  pharm_2012@126.com